Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204157 | 0.82 | L3MBTL1 (0.41) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL8520603 | 0.81 | CA2 (0.46) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL19071348 | 0.80 | MEN1 (0.46) | MEN1TP53KMT2ARECQLPOLB | |
| SCHEMBL9893028 | 0.79 | CNR2 (0.44) | MEN1KMT2AALDH1A1KDM4EPOLB | |
| SCHEMBL16480463 | 0.78 | MEN1 (0.50) | MEN1TP53KMT2ARECQLPOLB | |
| SCHEMBL28070422 | 0.77 | KMT2A (0.53) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL9891865 | 0.74 | MEN1 (0.46) | MEN1TP53KMT2ARECQLCNR2 | |
| SCHEMBL3708847 | 0.73 | MEN1 (0.48) | MEN1TP53KMT2ACNR2 | |
| SCHEMBL16254877 | 0.73 | MEN1 (0.48) | MEN1TP53KMT2ARECQLALDH1A1 | |
| SCHEMBL3708845 | 0.73 | MEN1 (0.48) | MEN1TP53KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | MEN1 4874/4885TP53 4450/4885KMT2A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.